Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin

Daniel D. Karp, Michael N. Pollak, Roger B. Cohen, Peter D. Eisenberg, Paul Haluska, Donghua Yin, Allan Lipton, Laurence Demers, Kim Leitzel, Mary L. Hixon, Leon W. Terstappen, Linda Garland, Luis G. Paz-Ares, Felipe Cardenal, Corey J. Langer, Antonio Gualberto

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin'. Together they form a unique fingerprint.

Medicine & Life Sciences